<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-116061</identifier>
<setSpec>0014-2565</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Burden of illness attributable to subclinical hypothyroidism in the Spanish population</dc:title>
<dc:description xml:lang="en">Introduction. Subclinical hypothyroidism (SH) has been associated recently to cardiovascular diseases. However, the loss of health it entails remains unknown. This study has assessed the burden of illness attributable to SH in Spain. Patients and methods. Based on the Spanish prevalence data found in international studies, a theoretical model was developed to estimate the Disability Adjusted Life Years (DALYs), Years of Life Lost (YLL) and Years Lost due to Disability (YLD) associated with SH. Prevalence of risk factors, coronary mortality risk and coronary event risk associated with SH were obtained from a review of the literature. An analysis was conducted according to the World Health Organization methodology approach for these studies, using official Spanish sources (hospital discharge records, minimum basic data set [MBDS], inpatient mortality records, etc. Results. In Spain, approximately 2,767,124 people have SH, specifically 1,949,820 with levels of TSH between 4.5 and 6.9mIU/l (70.5%), 538,988 with levels between 7 and 9.9mIU/l (19.5%), and 278,317 between 10 and 19.9mIU/l (10%). These subjects suffer approximately 12,608 cardiac events and 1,388 deaths a year attributed to their SH. This represents 30,550 DALYs (13,124 YLL and 17,426 YLD). Between 1.6 and 7.3% of cardiovascular DALYs can be attributed to SH. Conclusion. SH is a silent disease which considerably increases the burden of disease. Evaluation of SH, at least in patients belonging to risk groups, could be cost-effective (AU)</dc:description>
<dc:creator>Álvarez, J</dc:creator>
<dc:creator>Pérez-Alcántara, F</dc:creator>
<dc:creator>Balsa, J. A</dc:creator>
<dc:creator>Crespo, C</dc:creator>
<dc:creator>Donnay, S</dc:creator>
<dc:creator>Polanco, C</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Introducción. El hipotiroidismo subclínico (HS) se ha asociado a enfermedades cardiovasculares, pero se desconoce la pérdida de salud que conlleva. Hemos evaluado la carga de enfermedad del HS en España. Pacientes y métodos. A partir de la prevalencia del HS en España obtenida de estudios internacionales, se llevó a cabo un modelo teórico que calculó los años de vida ajustados por discapacidad (AVAD), los años de vida perdidos (AVP), y las pérdidas de salud por discapacidad (AVD) asociados al HS. Las prevalencias de los factores de riesgo, el riesgo de mortalidad coronaria, y de episodios coronarios asociados al HS se obtuvieron de una revisión de la literatura. El análisis se llevó a cabo según la metodología de la Organización Mundial de la Salud, utilizando fuentes oficiales españolas (registro de altas hospitalarias: conjunto mínimo básico de datos [CMBD], registro de mortalidad hospitalaria, etc.). Resultados. En España hay aproximadamente 2.767.124 personas con HS (1.949.820 con niveles de TSH entre 4,5 y 6,9mUI/l [70,5%], 538.988 con TSH entre 7 y 9,9mUI/l [19,5%], y 278.317 con TSH entre 10 y 19,9mUI/l [10%]). Estas personas con HS podrían sufrir 12.608 episodios cardiacos y 1.388 muertes cardiacas anuales, lo que representa 30.550 AVAD (13.124 AVP y 17.426 AVD). El HS puede representar entre el 1,6 y el 7,3% de los AVAD cardiovasculares. Conclusión. El HS es una condición silente que determina una enorme carga de enfermedad. La valoración del HS, al menos en los pacientes pertenecientes a grupos de riesgo, podría ser coste-efectiva (AU)</dc:description>
<dc:source>Rev Clin Esp;213(8): 363-369, nov. 2013.</dc:source>
<dc:identifier>ibc-116061</dc:identifier>
<dc:title xml:lang="es">Carga de la enfermedad atribuible al hipotiroidismo subclínico en la población española</dc:title>
<dc:subject>^d28422</dc:subject>
<dc:subject>^d50241</dc:subject>
<dc:subject>^d28612</dc:subject>
<dc:subject>^d30935^s22061</dc:subject>
<dc:subject>^d30935^s22083</dc:subject>
<dc:subject>^d30769</dc:subject>
<dc:subject>^d7217^s22054</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d28397</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d7217^s22080</dc:subject>
<dc:subject>^d28628</dc:subject>
<dc:type>article</dc:type>
<dc:date>201311</dc:date>
</metadata>
</record>
</ibecs-document>
